A Agroecologia na Escola Família Agrícola de Itaquiraí, em Mato Grosso do Sul.

bitstream/item/66246/1/31208.pdfOrganizado por: Alberto Feiden, Milton Parron Padovan, Adalgiza Inês Campolim, Aurélio Vinícius Borsato, Ivo de Sá Motta, João Batista Catto, Tércio Jacques Fehlauer

Luminescent anti-reflection coatings based on Er3+ doped forsterite for commercial silicon solar cells applications

Efficiency of solar devices is affected by several factors such as, devices surface reflection and the energy emitted in the ultraviolet and infrared regions, which are not harnessed by the cell, are among the main causes. To reduce these losses, we propose the use of rare-earth doped anti-reflection coatings. Erbium doped forsterite (Mg2SiO4:Er3+) thin films were synthesized in order to bind the anti-reflective property of forsterite films with the upconversion property of erbium ion. For the first time in literature, Mg2SiO4:Er3+ optical activity in the visible range with excitation at 1470 nm is presented. Single and double layers anti-reflective coating models, with forsterite as coating material, were simulated. The single layer model was compared to experimental data presenting elevated accordance. The coating application on silicon wafer leaded to a light absorption enhancement over 80% in the visible spectrum. The dopant influence on the films optical behavior was also studied indicating that despite the presence of erbium, the fosterite films preserved their anti-reflectivity. Moreover, the coatings were analyzed through chemical and mechanical resistance tests, indicating elevated scratch resistance (over 500 mN) and chemical stability at high humidity and corrosive environments. Mg2SiO4:Er3+ films revealed to be a promising anti-reflection coating for increasing commercial silicon-based solar cells efficiency

Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)

Background: Obesity has been associated with improved response to immunotherapy in cancer patients. We investigated the role of body mass index (BMI) in patients from the ARON-1 study (NCT05287464) treated by dual immuno-oncology agents (IO+IO) or a combination of immuno-oncology drug and a tyrosine kinase inhibitors (TKI) as first-line therapy for metastatic renal cell carcinoma (mRCC). Patients and methods: Medical records of patients with documented mRCC treated by immuno-oncology combinations were reviewed at 47 institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (OS), and overall clinical benefit (OCB), defined as the sum of the rate of partial/complete responses and stable disease. Univariate and multivariate analyses were used to explore the association of variables of interest with survival. Results: A total of 675 patients were included; BMI was >25 kg/m2 in 345 patients (51%) and was associated with improved OS (55.7 vs. 28.4 months, P < .001). The OCB of patients with BMI >25 kg/m2 versus those with BMI ≤25 kg/m2 was significantly higher only in patients with nonclear cell histology (81% vs. 65%, P = .011), and patients with liver metastases (76% vs. 58%, P = .007), Neutrophil to lymphocyte ratio >4 (77% vs 62%, P = .022) or treated by nivolumab plus ipilimumab (77% vs. 64%, P = .044). In the BMI ≤25 kg/m2 subgroup, significant differences were found between patients with NLR >4 versus ≤4 (62% vs. 82%, P = .002) and patients treated by IO+IO versus IO+TKIs combinations (64% vs. 83%, P = .002). Conclusion: Our study suggests that the prognostic significance and the association of BMI with treatment outcome varies across clinico-pathological mRCC subgroups